Current Trials
How to Refer a Patient for Phase I Assessment
Email: phase1cancer@uclh.nhs.uk Telephone: +44 (0)20 3447 6036
Post: Kerry Guile, Lead Nurse, Clinical Research Facility, EGA Wing, UCH,
235 Euston Road London NW1 2BU
EudraCT # |
Study full title |
Principal Investigator |
| Generic | ||
| 2012-000832-24 | A Phase I Open-Label, Ascending Dose Cohort Study of CO-101 and Cisplatin in Patients with Advanced Solid Tumors followed by an Expanded Cohort of Patients with Stage IIIb/IV NSCLC | Dr. Rebecca Kristeleit |
| 2009-017817-31 | Phase I Open-label, Dose Escalation Study of S-222611 in Patients with Solid Tumours | Dr. Martin Foster |
| 2011-005185-37 | A Randomized, Open-label, Single Dose, Two-way Cross Over Study to Investigate the Relative Bioavailability of Capecitabine in Rapid Disintegrating Tablets (RDT) Versus the Commercial Xeloda® Tablets Following Oral Administrations in Adult Patients with Solid Tumors | Dr. Rebecca Kristeleit |
| 2010-022442-25 | A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects with Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma | Dr. Tim Meyer |
| 2010-024237-23 | An open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients with Advanced Solid Tumors | Dr. Rebecca Kristeleit |
| 2010-024291-25 | Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Doxorubicin in Non-heavily Pretreated Patients with Selected Advanced Solid Tumors | Dr. Martin Foster |
| 2010-024239-18 | Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Gemcitabine in Non-heavily Pretreated Patients with Selected Advanced Solid Tumors | Dr. Martin Foster |
| 2010-023655-28 | An open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects with Unresectable Solid Tumors | Dr. Rebecca Kristeleit |
| 2011-004250-26 | A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Breast Cancer or Other Solid Tumor | Dr. Rebecca Kristeleit |
| Breast | ||
| 2010-024454-10 | An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer | Prof. Charles Swanton |
| 2006-002348-27 | A phase II Proof of Principle Trial of the activity of the PARP-1 inhibitor, AG-014699, in known carriers of a BRCA1 or BRCA2 mutation with locally advanced or metastatic breast or advanced ovarian cancer | Dr. Alison Jones |
| 2007-003240-30 | A phase I/II open label study to evaluate the safety, endocrine effects and anti-tumour activity of Abiraterone Acetate (CB7630) in patients with oestrogen (ER) or androgen receptor (AR) positive advanced or metastatic breast carcinoma | Dr. Rob Stein |
| Gastro-Intestinal | ||
| 2012-000317-36 | A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels | Prof. Daniel Hochhauser |
| 2010-022983-11 | A randomized, multicenter, open-label phase II study of RO5083945 in combination with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wild-type or mutant metastatic colorectal cancer | Dr. John Bridgewater |
| 2010-019602-16 | An open label phase Ib study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 over-expressing oesophago-gastric cancer Assess ability of ex vivo molecular response to predict molecular response | Prof. Daniel Hochhauser |
| Endometrial | ||
| 2011-000266-35 | A phase II, open-label, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced endometrial cancer | Dr. Rebecca Kristeleit |
| 2011-003062-32 | A randomized phase II non-comparative study of the efficacy of PF-04691502 and PF-05212384 in patients with recurrent endometrial cancer | Dr. Rebecca Kristeleit |
| Gynea | ||
| 2009-010319-34 | A phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients with Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | Dr. Rebecca Kristeleit |
| 2008-003697-18 | A phase I, randomised, 2 period cross over study to determine the comparative bioavailability of two different oral formulations of AZD2281 in cancer patients with advanced solid tumours | Prof. Jonathan Ledermann |
| 2008-001551-22 | A randomized, double-blind, placebo controlled, multi-center, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) to first line chemotherapy in patients with optimally debulked ( < 1 cm ) epithelial ovarian cancer. | Prof. Jonathan Ledermann |
| 2006-002348-27 | A phase II Proof of Principle Trial of the activity of the PARP-1 inhibitor, AG-014699, in known carriers of a BRCA1 or BRCA2 mutation with locally advanced or metastatic breast or advanced ovarian cancer | Dr. Alison Jones |
| 2007-003240-30 | A phase I/II open label study to evaluate the safety, endocrine effects and anti-tumour activity of Abiraterone Acetate (CB7630) in patients with oestrogen (ER) or androgen receptor (AR) positive advanced or metastatic breast carcinoma | Dr. Rob Stein |
| Haematology | ||
| 2011-001914-33 | A Phase I/IIa, Dose-Escalation, Study of CHR-3996 in Combination with Tosedostat in Participants with Relapsed, Refractory Multiple Myeloma | Prof. Kwee Yong |
| 2010-022442-25 | A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects with Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma | Dr. Tim Meyer |
| 2010-023772-71 | An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment | Prof. Kwee Yong | 2010-022445-20 | A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma | Dr. Neil Rabin | 2010-023964-42 | A Dose Escalation Study Phase 1, Two-arm, Open-label Study of Once Daily, Oral BMN673 in Patients With Advanced Hematological Malignancies | Prof. Asim Khwaja |
| Hepatobiliary | ||
| 2009-011924-14 | A multicentre, open label, phase I / Randomized, Double-Blind, Placebo-controlled Phase 2 study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with Sorafenib for advanced hepatocellular carcinoma patients | Dr. Tim Meyer |
| 2011-003574-84 | A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients with Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC) | Dr. Tim Meyer |
| 2010-018522-39 | A phase Ib study of Cisplatin, Gemcitabine and AZD6244 in patients with advanced Biliary Tract Cancer | Dr. John Bridgewater |
| Lung | ||
| 2010-022950-17 | A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with Advanced Solid Tumors including Extensive Stage Small Cell Lung Cancer | Dr. Martin Foster |
| 2010-020916-12 | A randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI 906 plus Erlotinib (Tarceva®), or Erlotinib plus Placebo in Patients with Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC | Dr. Martin Foster |
| 2010-019707-32 | A phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology | Dr. Martin Foster |
| Neuro | ||
| 2009-015971-28 | A phase I trial of IMA950 (a novel multi-peptide vaccine) plus GM-CSF in patients with newly diagnosed glioblastoma | Dr. Paul Mulholland |
Page last Modified: 19 October 2012 |
||
